Sun J, Tian Y, Yang C
Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(1):231-241.
PMID: 39158733
DOI: 10.1007/s00210-024-03346-7.
Sethi S, Shakyawar S, Reddy A, Patel J, Guda C
Diagnostics (Basel). 2024; 14(12).
PMID: 38928699
PMC: 11202902.
DOI: 10.3390/diagnostics14121284.
Bialy S, Iwaszko M, Swierkot J, Kolossa K, Wielinska J, Jeka S
Immunol Res. 2024; 72(4):614-625.
PMID: 38714580
PMC: 11347466.
DOI: 10.1007/s12026-024-09488-3.
Mu Y, Guan X
Curr Med Chem. 2024; 31(13):1634-1645.
PMID: 38666504
DOI: 10.2174/0929867330666230324152532.
Sabag B, Puthenveetil A, Levy M, Joseph N, Doniger T, Yaron O
EMBO J. 2024; 43(13):2552-2581.
PMID: 38637625
PMC: 11217363.
DOI: 10.1038/s44318-024-00094-5.
Single-Cell Analysis Reveals Malignant Cells Reshape the Cellular Landscape and Foster an Immunosuppressive Microenvironment of Extranodal NK/T-Cell Lymphoma.
Li Y, Luo C, Jiang J, He S, Liu Y, Yan W
Adv Sci (Weinh). 2023; 10(36):e2303913.
PMID: 37949673
PMC: 10754138.
DOI: 10.1002/advs.202303913.
Dysregulation of DNAM-1-Mediated NK Cell Anti-Cancer Responses in the Tumor Microenvironment.
Paolini R, Molfetta R
Cancers (Basel). 2023; 15(18).
PMID: 37760586
PMC: 10527063.
DOI: 10.3390/cancers15184616.
CD155 and Its Receptors as Targets for Cancer Therapy.
Paolini R, Molfetta R
Int J Mol Sci. 2023; 24(16).
PMID: 37629138
PMC: 10455395.
DOI: 10.3390/ijms241612958.
NK cells encapsulated in micro/macropore-forming hydrogels via 3D bioprinting for tumor immunotherapy.
Kim D, Jo S, Lee D, Kim S, Seok J, Yeo S
Biomater Res. 2023; 27(1):60.
PMID: 37349810
PMC: 10286468.
DOI: 10.1186/s40824-023-00403-9.
Local γδ T cells: translating promise to practice in cancer immunotherapy.
Zlatareva I, Wu Y
Br J Cancer. 2023; 129(3):393-405.
PMID: 37311978
PMC: 10403623.
DOI: 10.1038/s41416-023-02303-0.
Anti-human-TIGIT agonistic antibody ameliorates autoimmune diseases by inhibiting Tfh and Tph cells and enhancing Treg cells.
Kojima M, Suzuki K, Takeshita M, Ohyagi M, Iizuka M, Yamane H
Commun Biol. 2023; 6(1):500.
PMID: 37161050
PMC: 10170076.
DOI: 10.1038/s42003-023-04874-3.
MD Simulation Reveals Regulation of Mechanical Force and Extracellular Domain 2 on Binding of DNAM-1 to CD155.
Fang L, Zhao Y, Guo P, Fang Y, Wu J
Molecules. 2023; 28(6).
PMID: 36985819
PMC: 10053669.
DOI: 10.3390/molecules28062847.
CD96 as a Potential Immune Regulator in Cancers.
Feng S, Isayev O, Werner J, Bazhin A
Int J Mol Sci. 2023; 24(2).
PMID: 36674817
PMC: 9866520.
DOI: 10.3390/ijms24021303.
V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy.
Zhou X, Khan S, Huang D, Li L
Front Immunol. 2022; 13:938470.
PMID: 36189222
PMC: 9520664.
DOI: 10.3389/fimmu.2022.938470.
High expression of nectin-1 indicates a poor prognosis and promotes metastasis in hepatocellular carcinoma.
Wang X, Xing Z, Chen H, Yang H, Wang Q, Xing T
Front Oncol. 2022; 12:953529.
PMID: 36059705
PMC: 9433868.
DOI: 10.3389/fonc.2022.953529.
Immune cellular components and signaling pathways in the tumor microenvironment.
Yenyuwadee S, Aliazis K, Wang Q, Christofides A, Shah R, Patsoukis N
Semin Cancer Biol. 2022; 86(Pt 2):187-201.
PMID: 35985559
PMC: 10735089.
DOI: 10.1016/j.semcancer.2022.08.004.
CD155 promotes radioresistance and malignancy of esophageal cancer by regulating Hippo-YAP pathway.
Xin H, Liu Y, Chen P, Yin T, Wang M, Liu T
Discov Oncol. 2022; 13(1):53.
PMID: 35768666
PMC: 9243211.
DOI: 10.1007/s12672-022-00515-z.
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways.
Kraehenbuehl L, Weng C, Eghbali S, Wolchok J, Merghoub T
Nat Rev Clin Oncol. 2021; 19(1):37-50.
PMID: 34580473
DOI: 10.1038/s41571-021-00552-7.
Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development.
Rotte A, Sahasranaman S, Budha N
Biomedicines. 2021; 9(9).
PMID: 34572463
PMC: 8472042.
DOI: 10.3390/biomedicines9091277.
Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer.
Buckle I, Guillerey C
Cancers (Basel). 2021; 13(17).
PMID: 34503073
PMC: 8428224.
DOI: 10.3390/cancers13174263.